CPBIO Holding Co (HKSE:03839) FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:03839 CPBIO Holding Co Ltd HKSE:03839
71 GF Score
Price HK$9.20
GF Value HK$4.36
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is CPBIO Holding Co FFO?

FFO (Funds from operations) only applies to REITs.

HKSE:03839
71GF Score
CPBIO Holding Co Ltd HKSE:03839
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is CPBIO Holding Co (HKSE:03839) Overvalued in 2026?

Based on GuruFocus' analysis, CPBIO Holding Co stock appears to be overvalued. The current stock price of HK$9.20 is trading 110.9% above its estimated GF Value™ of HK$4.36. GuruFocus considers CPBIO Holding Co to be Significantly Overvalued.

Key valuation signals for HKSE:03839:

  • FFO:
  • GF Value™: HK$4.36 vs. price of HK$9.20 (110.9% above fair value)
  • GF Score™: 71/100 with 4 warning signs

No single metric tells the full story. See the HKSE:03839 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


CPBIO Holding Co Business Description

Address 16 Harcourt Road, 21st Floor, Far East Finance Centre, Central, Hong Kong, HKG
Chia Tai Enterprises International Ltd is engaged in the manufacture and sale of animal health products and chlortetracycline (CTC). The group has two reportable segments: Biotech Business and Investment Business. The Biotech Business segment is involved in the manufacture and/or sale of animal health products and chlortetracycline. The Investment Business segment is engaged in the trading of machinery and the manufacture and sale of automotive parts through the group's joint ventures and associates. It generates the majority of its revenue from the Biotech Business segment. Its geographical segments are Mainland China, which generates key revenue, Asia Pacific (excluding mainland China), the Americas, Europe, and Others.
71GF Score

Get the complete analysis for HKSE:03839

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$9.20
Price
HK$4.36
GF Value